Virginia Commonwealth University

VCU Massey Cancer Center

Clinical trial tests promising immunotherapies for advanced lung cancer

Sherman Baker Jr., M.D., medical oncologist and member of the Developmental Therapeutics research program at VCU Massey Cancer Center, is spearheading a phase 3 clinical trial testing two immunotherapy drugs, MEDI4736 and tremelimumab, for the treatment of patients with advanced lung cancer. The goal of the study is to determine whether MEDI4736 combined with tremelimumab or MEDI4736 by itself is more effective than traditional chemotherapy treatment to treat advanced lung cancer.

Continue reading →

Massey researcher awarded $3 million to study the effect of blood cell stimulation on the development of adolescent leukemia and bone marrow disorders

Massey program leader, researcher and physician Seth Corey M.D., M.P.H., was awarded more than $3 million in grant funding from the National Heart, Lung and Blood Institute (NHLBI) for a four-and-a-half-year study on the evolution of a blood cell deficiency to pre-leukemia. The research aims to determine whether a common treatment for the condition acts as a contributor to the development of leukemia or other life-threatening bone marrow disorders.

Continue reading →

A second first birthday

Six months after her original cancer diagnosis, Ann Moore sat in a clinic exam room anticipating the results from her CT scan. In February 2015, she had received the last of 18 weeks worth of chemotherapy treatment for stage IV ovarian cancer, and now waited anxiously to hear if it had been effective.

Continue reading →

Integrative health myths & facts: sugar & cancer

There has been a lot of buzz about sugar making cancer cells grow faster and causing the cancer to spread faster, but what does the research suggest? 

Continue reading →

VCU Massey researchers uncover process that drives prostate cancer metastasis

Zheng Fu, Ph.D.

Researchers at VCU Massey Cancer Center have uncovered a novel function of the gene PLK1 (polo-like kinase 1) that helps prostate cancer cells metastasize (spread) to other parts of the body. This mechanism highlights new potential targets for cancer therapies and challenges the previous understanding of PLK1’s role in cancer growth and progression. 

Continue reading →